<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819194</url>
  </required_header>
  <id_info>
    <org_study_id>CR-5282</org_study_id>
    <nct_id>NCT01819194</nct_id>
  </id_info>
  <brief_title>Contact Lens Comfort Relative to Meibomian Gland Status</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to establish a correlation between patient reported comfort while using soft
      contact lenses and meibomian gland dysfunction (MGD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comfort as Measured by the Contact Lens Users Experience Questionnaire (CLUE)</measure>
    <time_frame>Post 3 days of wear</time_frame>
    <description>CLUE is survey that is used to assess subjective comfort of the test article. The higher the score the better on a range of 0 to 120.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Meibbomian Gland Dysfunction (MGD)as Measured by MGD Scale</measure>
    <time_frame>Post 3 days of wear</time_frame>
    <description>Meibomian Gland Dysfunction (MGD) as measured using the MGD 0 - 11 scale translated into grades 0 to 3 where 0 refers to absence of markers.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acuvvue Oasys with Hydaclear Plus with 38% water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon A</intervention_name>
    <arm_group_label>senofilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject must be able to read, understand, and sign the statement of informed
             consent and receive a fully executed copy of the form.

          2. The subject be able and willing to adhere to the instructions set forth in this
             clinical protocol.

          3. The subject must be 18 and less than 39 years of age.

          4. The subject must be an adapted soft contact lens wearer in both eyes (Defined as
             having been a full times lens wearer for at least 3 months).

          5. Subjects must be current full time daily wearers of Acuvue Oasys lenses (defined as,
             at least 6 hours per day, 5 days per week).

          6. The subject's spherical equivalent distance refraction must be in the range of 0.00 to
             -6.00D in each eye.

          7. The subject must present at visit 1 with a current copy of their spectacle
             prescription.

          8. The subject must have the best corrected visual acuity of 0.18 or better in each eye
             as assessed by LogMAR chart.

          9. The subject must have normal eyes (i.e., no ocular medication, or infections of any
             type)

        Exclusion Criteria:

          1. Wear Acuvue Oasys with Hydraclear Plus on an extended wear basis.

          2. Wear Acuvue Oasys with Hydraclear Plus for astigmatism.

          3. History of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia, active
             or recent varicella, viral disease of the cornea and/or conjunctiva; chronic bacterial
             disease of the cornea and/or conjunctiva; mycobacterial infection of the eye; and/or
             fungal disease of the eye.

          4. Use of concomitant ocular medications during the study period. Topical artificial
             tears or contact lens lubricants are allowed, but no instillation on the day of
             examinations.

          5. Any systemic disease, autoimmune disease, or use of medications, which may interfere
             with contact lens wear.

          6. Subjects using medications influencing tear production such as steroids,
             immunosuppressive agents and/or anti-cholinergics (e.g. cold and allergy medications,
             tricyclic antidepressants) for treatment of autoimmune connective tissue disease may
             not be enrolled in this study if they have not been on a stable dosing regimen for 30
             days prior to the Eligibility Visit. Subjects may use birth control medications since
             there is inconclusive evidence relative to the influence on tear film.

          7. Any infectious disease (e.g. Hepatitis, tuberculosis) or a contagious
             immunosuppressive disease (e.g. HIV, by self report).

          8. Subjects reporting discomfort at screening visit related to fit or care system
             abnormalities (both determined by the investigator), ocular conditions such as
             conjunctival infections, iritis.

          9. Currently pregnant or lactating (subjects who become pregnant during the study will be
             discontinued).

         10. Any ocular or systemic allergies or diseases that may interfere with contact lens
             wear.

         11. Entropion, ectropion, extrusion, chalazia, recurrent styes, glaucoma, history of
             recurrent corneal erosion,aphakia, or moderate or above corneal distortion by
             keratometry.

         12. Any previous, or planned, ocular or intraocular surgery (radial keratotomy, LASIK,
             ETC.)

         13. Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization,
             corneal staining, tarsal abnormalities, conjunctival injection) on the FDA
             classification scale, any previous history or signs of a contact lens-related corneal
             inflammatory event (e.g. past peripheral ulcer or round peripheral scar), or any other
             ocular abnormality that may contraindicate contact lens wear.

         14. Any corneal distortion resulting from previous hard or rigid gas permeable contact
             lens wear.

         15. Monovision or multi-focal contact lens correction

         16. Participation in any contact lens or lens care product clinical trial within 30 days
             prior to study enrollment

         17. History of binocular vision abnormality or strabismus

         18. History of serious mental illness

         19. History of seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <results_first_submitted>December 2, 2014</results_first_submitted>
  <results_first_submitted_qc>December 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2014</results_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 64 subjects were enrolled in this study. Of the enrolled subjects 2 did not meet the eligibility criteria and 62 were dispensed a study lens. Of the dispensed subjects 60 completed the study and 2 were discontinued.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall</title>
          <description>Subjects only wore one lens: senofilcon A, 38% water. Subjects, were enrolled and screened per inclusion/exclusion criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Loss of study articles</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>64 subjects enrolled with 60 Completing</population>
      <group_list>
        <group group_id="B1">
          <title>Dispensed Subjects</title>
          <description>All subjects that were dispensed the study lens.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.53" spread="3.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comfort as Measured by the Contact Lens Users Experience Questionnaire (CLUE)</title>
        <description>CLUE is survey that is used to assess subjective comfort of the test article. The higher the score the better on a range of 0 to 120.</description>
        <time_frame>Post 3 days of wear</time_frame>
        <population>Subjects are those who were enrolled, randomized, and completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A, 38% Water</title>
            <description>Senofilcon A, 38% water</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort as Measured by the Contact Lens Users Experience Questionnaire (CLUE)</title>
          <description>CLUE is survey that is used to assess subjective comfort of the test article. The higher the score the better on a range of 0 to 120.</description>
          <population>Subjects are those who were enrolled, randomized, and completed the study per protocol.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.67" spread="18.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Meibbomian Gland Dysfunction (MGD)as Measured by MGD Scale</title>
        <description>Meibomian Gland Dysfunction (MGD) as measured using the MGD 0 – 11 scale translated into grades 0 to 3 where 0 refers to absence of markers.</description>
        <time_frame>Post 3 days of wear</time_frame>
        <population>Subjects analyzed are those who enrolled, randomized, and completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A, 38% Water</title>
            <description>Senofilcon A, 38% water</description>
          </group>
        </group_list>
        <measure>
          <title>Meibbomian Gland Dysfunction (MGD)as Measured by MGD Scale</title>
          <description>Meibomian Gland Dysfunction (MGD) as measured using the MGD 0 – 11 scale translated into grades 0 to 3 where 0 refers to absence of markers.</description>
          <population>Subjects analyzed are those who enrolled, randomized, and completed the study per protocol.</population>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected over the course of the study, approximately 1 week.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Senofilcon A, 38% Water</title>
          <description>Senofilcon A, 38% water</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daria Wicks</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-1391</phone>
      <email>RA-VISUS-ClnclStds@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

